Bram Wieskopf, MD
Internal Medicine · Woodstock, GANPI 1164472577
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,573 of the $2,235 with a category attached, or 70.4%. 16 manufacturers reported payments, led by Lilly USA, LLC at 35.0% of the total. Reporting peaked in 2019 at $1,032 and has fallen 90.8% since, to $95 in 2025.
Across 79 payments — averaging $28.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$783
- Amgen$335
- Radius Health, Inc.$213
- Eli Lilly$187
- Sanofi-aventis U.S. LLC$134
- Novo Nordisk$118
- plus $465 from 10 others
Across 743 payments — averaging $29,945 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$17.6M
- Regeneron$1.5M
- AstraZeneca$1M
- AbbVie$900K
- Pfizer$435K
- Seqirus USA Inc$309K
- plus $480K from 11 others
What the payments were for
- Consulting fees$65029%
- Food & beverage$1,57370%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 8 | $783 |
| Amgen | 14 | $335 |
| Radius Health, Inc. | 5 | $213 |
| Eli Lilly | 5 | $187 |
| Sanofi-aventis U.S. LLC | 10 | $134 |
| Novo Nordisk | 7 | $118 |
| AstraZeneca | 8 | $114 |
| AbbVie(2 entities) | 5 | $77 |
| Pfizer | 4 | $63 |
| Amarin Pharma, Inc. | 4 | $60 |
| Boehringer Ingelheim | 3 | $57 |
| GSK | 2 | $30 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,235 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 123 | $139,017 |
| JardianceEmpagliflozin | 27 | $32,356 |
| TrulicityDulaglutide | 18 | $19,954 |
| EliquisApixaban | 12 | $16,205 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $15,605 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,178 |
| Rosuvastatin Calcium | 213 | $2,154 |
| Nebivolol Hcl | 24 | $1,882 |
| SynthroidLevothyroxine Sodium | 23 | $1,694 |
| Olmesartan Medoxomil | 65 | $1,609 |
| Tramadol Hcl ErTramadol Hcl | 12 | $1,419 |
| Gabapentin | 61 | $1,280 |
| Levothyroxine Sodium | 159 | $1,263 |
| Pantoprazole Sodium | 85 | $1,225 |
| Atorvastatin Calcium | 110 | $1,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $783 | $158,971141 claims |
| Boehringer IngelheimJardiance | $57 | $32,35627 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $30 | $19,78324 claims |
| PfizerEliquis | $63 | $16,20512 claims |
| AbbVieSynthroid | $77 | $1,69423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Woodstock
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.